Trump administration revises rebate pilot for 340B drug discount program

Ed’s tales discover prescription drug pricing, affordability and entry, as nicely points surrounding patents, litigation, and laws. He’s additionally the writer of the morning Pharmalittle e-newsletter and the afternoon Pharmalot e-newsletter.

The Trump administration has revised the phrases of a pilot effort that may enable some drugmakers to supply rebates to sure hospitals and clinics for bought medicines, a controversial transfer that will remodel a key tenet of a federal drug low cost program.

The anticipated pilot for the 340B Drug Pricing Program, which is slated to enter impact on Jan. 1, 2027, will enable pharmaceutical corporations to offer “well timed” rebates, quite than providing upfront reductions. This system targets particular medication and pharmaceutical corporations which are concerned within the first two rounds of the Medicare Drug Worth Negotiation Program.

“This revised pilot helps modernize program oversight by enhancing visibility into 340B transactions whereas serving to protect this system’s long-term sustainability for the sufferers and communities it was created to serve,” stated Tom Engels, who heads the Well being Sources and Companies Administration, the federal government company that oversees this system, in a press release.